Comparison of clinical efficacy of different neoadjuvant chemotherapy regimens for triple negative breast cancer
TONG Wenxian;HE Anbing;LIU Aihua;PENG Xiulan;WANG Hu;TIAN Qian;LI Xiaoguang;XU Huilin;Department of Oncology,Fifth Hospital in Wuhan;
objective To investigate the clinical efficacy of different neoadjuvant chemotherapy regimens in the treatment of triple negative breast cancer(TNBC). Method Ninety-six patients with TNBC who received neoadjuvant chemotherapy were divided into experiment 1 group(n=48) and experiment 2 group(n=48) in accordance with the random number table. Patients in experiment 1 group were given docetaxel ~+ epirubicin chemotherapy, Patients in experiment 2 group were given cyclophosphamide~+epirubicin~+fluorouracil chemotherapy. The inflammatory cytokines levels of interleukin-6(IL-6), interleukin-8(IL-8), interleukin-1β(IL-1β), tumor necrosis factor-α(TNF-α) in two groups before and after chemotherapy, the factor levels CD3~+CD4~+, CD3~+CD56~+, CD3~+CD4~+/CD3~+CD8~+T-cell before and after treatment and the adverse reactions were investigated. Result After the chemotherapies, the levels of IL-6, IL-8, IL-1β, TNF-α were decreased than those before chemotherapy and the levels of IL-6, IL-8, IL-1β, TNF-α levels in experiment 1 group were lower than those in experimental group 2; the levels of CD3~+CD4~+, CD3~+CD56~+, CD3~+CD4~+/CD3~+CD8~+were increased than those before chemotherapy, and the levels of CD3~+CD4~+, CD3~+CD56~+, CD3~+CD4~+/CD3~+CD8~+in experiment 1 group levels were higher than those in experiment 2 group, all the differences above were statistically significant(P0.05). The ORR of experiment 1 group was 64.58%, which was significantly higher than that of experiment 2 group(43.75%)(P0.05). There was no significant difference between the two groups in the adverse reactions of hematologic toxicity, gastrointestinal toxicity and bone marrow suppression(P0.05). Conclusion The neoadjuvant chemotherapy regimen of docetaxel ~+ epirubicin in the treatment of patients with TNBC can be effective in restoring immune imbalance, with clinical efficacy, without increasing of adverse reactions, which is worthy of clinical applications.
【CateGory Index】： R737.9